Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Selecta Biosciences (SELB)

Selecta Biosciences (SELB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Selecta Biosciences 65 Grove Street Watertown MA 02472 USA

https://selectabio.com P: 617-923-1400

Description:

Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States.

Key Statistics

Overview:

Market Capitalization, $K 136,766
Enterprise Value, $K 56,596
Shares Outstanding, K 155,204
Annual Sales, $ 110,780 K
Annual Net Income, $ 35,380 K
Last Quarter Sales, $ 5,250 K
Last Quarter Net Income, $ -11,390 K
EBIT, $ -47,120 K
EBITDA, $ -46,210 K
60-Month Beta 0.84
% of Insider Shareholders 31.20%
% of Institutional Shareholders 41.95%
Float, K 106,780
% Float 68.80%
Short Volume Ratio 0.21

Growth:

1-Year Return -42.78%
3-Year Return -72.63%
5-Year Return -84.99%
5-Year Revenue Growth 52,652.38%
5-Year Earnings Growth 97.50%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.07 on 08/17/23
Latest Earnings Date 11/16/23
Earnings Per Share ttm -0.22
EPS Growth vs. Prev Qtr 36.36%
EPS Growth vs. Prev Year -216.67%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

SELB Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -44.13%
Return-on-Assets % -22.00%
Profit Margin % 31.94%
Debt/Equity 0.21
Price/Sales 1.34
Price/Cash Flow 9.91
Price/Book 2.07
Book Value/Share 0.43
Interest Coverage 12.48
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar